A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer.

Inclusion Criteria

• •Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
• •A life expectancy of at least 3 months
• •Ability to swallow oral study drug
• •Have adequate organ and marrow function as confirmed by the laboratory values listed below, obtained within 28 days prior to the first dose of study treatment:
• •Bone marrow function assessments (without transfusion within 28 days prior to receipt of study treatment):
• •1. ANC \>= 1500 cells/uL (1.5 x 10\^9/L) without granulocyte-colony stimulating factor support
• •2. Platelet count \>= 100.0 x 10\^9/L
• •3. Hemoglobin \>= 9 g/dL (or 5.6 mmol/L)
• •Chemistry panel assessments:
• •1. AST and ALT \<= 1.5 x upper limit of normal (ULN); if liver metastases, \<= 2.5 x ULN
• •2. Bilirubin \<= 1.5 x ULN (\<= 3 x ULN if hyperbilirubinemia is due to Gilbert's syndrome)
• •3. Serum albumin \>= 3.0 g/dL
• •4. Serum creatinine \<= 1.5 x ULN or creatinine clearance \>= 50 mL/min
• •5. Fasting glucose \<= 150 mg/dL and hemoglobin A1c \<= 7.5%
• •Resolved or stabilized toxicities resulting from previous therapy to Grade 1 (except for alopecia and neuropathy).
• •Have a histologically confirmed diagnosis of ovarian (Part 1 only), breast (Part 1 only) or prostate cancer (Part 1 and Part 2)
• •Disease must be either metastatic or locally advanced disease that cannot be treated with curative intent
• •For patients with ovarian cancer (Part 1 only):
• •1. High-grade (2 or 3) serous or endometrioid or clear cell epithelial ovarian, fallopian tube, or primary peritoneal cancer (PPC)
• •2. Must have received at least one prior platinum-based therapy and may have platinumsensitive disease (i.e., documented radiologic disease progression \>= 6 months following the last dose of the platinum treatment administered) or platinum-resistant disease
• •3. Have a CA-125 level that is \> 2 x ULN
• •4. Must have measurable disease by RECIST v1.1
• •For patients with breast cancer (Part 1 only): must be human epidermal growth factor receptor 2 negative (HER2-) (estrogen receptor \[ER\]/progesterone positive or negative):
• •1. ER/progesterone-positive patients must have received and progressed on at least one endocrine therapy (adjuvant or metastatic)
• •2. ER/progesterone-negative/HER2- (triple-negative breast cancer \[TNBC\]) patients must have received at least one prior line of chemotherapy for metastatic breast cancer
• •3. Must not have received more than two prior lines of chemotherapy for metastatic breast cancer
• •4. Must have measurable disease by RECIST v1.1
• •For patients with prostate cancer:
• •1. Adenocarcinoma of the prostate without small cell or neuroendocrine features
• •2. Surgical or medical castration with testosterone \< 50 ng/dL (1.7 nM)
• •3. Patients treated with luteinizing hormone-releasing hormone analogs must have initiated therapy at least 4 weeks prior to the first dose of study treatment and continue throughout the study treatment
• •4. Progression of prostate cancer either via PSA progression (two rising PSA levels measured \>= 1 week apart, with second result \>= 1 ng/mL) or radiographic progression with or without PSA progression
• •5. Must have received at least one prior line of second-generation androgen receptor targeted therapy (e.g., abiraterone, enzalutamide, apalutamide)
• •6. Patients with prostate cancer must have either measurable disease by RECIST v1.1 or bone lesions by bone scan, or both.
• •* Submission of a formalin-fixed, paraffin-embedded (FFPE) tumor tissue block or a minimum of 12 freshly cut, unstained, serial tumor slides from the most recently collected tumor tissue for central molecular analysis (retrospective NGS testing for HR and PI3K-AKT pathway status and for other protocol-mandated secondary and exploratory assessments). Cytologic or fine needle aspirate samples are not acceptable. Tumor tissue from bone metastases is not acceptable.
• •* For men and women of child bearing potential: agreement to remain abstinent or use protocol defined contraceptive measures during the treatment period and for at least 28 days after the last dose of ipatasertib,or 6 months after the last dose of rucaparib, whichever occurs later